NewGenIvf plans to use offering proceeds to expand Nodexus cytometry technology
NIVF•
NIVF•NewGenIvf plans to use net proceeds from an approximately $2.5 million offering, together with existing cash, to expand Nodexus cytometry technology and its assisted reproductive services platform. About $625,000 of gross proceeds will fund repurchase of $584,112 in Exchange Note principal.
NewGenIvf plans to fund commercialization and expansion of Nodexus advanced cytometry technology and its assisted reproductive services platform with net proceeds from an approximately $2.5 million offering and existing cash. Other planned uses include strategic investments in prediction-market and digital-asset/AI initiatives, UAE real estate interests and general corporate purposes. Approximately $625,000 of gross proceeds will fund repurchase of $584,112 in principal amount of the Exchange Note.